Former Cochlear CEO Dr. Chris Roberts AO joins Atmo Biosciences Board
29 October 2019 Melbourne, Australia Former Cochlear Chief Executive Officer Dr. Chris Roberts AO has been appointed as a Non-Executive Director to the Board of Atmo Biosciences, a digital health business commercializing a world-first ingestible gas-sensing capsule that…
What’s Holding Up Digital Pathology?
28 October 2019 By Richard Lash MD, and Caroline Popper MD For centuries, the basics of pathologic examination of human tissue under a microscope has essentially remained unchanged. The excitement about Digital Pathology (creating digital images of the…
Ransomware – A first-hand account
28 October 2019 By Dr Irving Hofman RYUK is a sophisticated cryptoware with ransom requests of the order of half a million US dollars. The healthcare sector in Australia has become a specific target. Recently, the Exigence cybersecurity…
Dimerix awarded second Innovation Connections Grant
23 October 2019 MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical-stage drug development company, announced today that it has been awarded a second Innovation Connections Grant, which is supported by the Australian Government’s Department of Industry, Innovation and…
Dr Jennifer Rosenthal Appointed Clarity Pharmaceuticals Director of Quality and Regulatory Affairs
23 October 2019 Sydney, Australia – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Jennifer Rosenthal as Director of Quality and Regulatory Affairs. Jennifer has more…
SeerPharma Journal October 2019
24 October 2019 SeerPharma is excited to publish the final issue of our Journal for 2019. With articles on our activities with customers and attendance at major industry events in the APAC region. We hope you find something…
FDA grants Orphan Drug Designation for NNZ-2591 to treat Phelan-McDermid syndrome and Pitt Hopkins syndrome
16 October Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of each of Phelan-McDermid syndrome and Pitt Hopkins syndrome.…
CSIROscope: How do you mend a broken heart?
16 October 2019 By Ali Green Sunday was World Heart Day and we celebrated in true CSIRO style – with science and technology. In a world-first, a man in the US received a replacement heart valve. It was…
Bionics Institute receives comprehensive ISO 9001 accreditation covering all operations, research and development processes
16 October 2019 The Bionics Institute is the first and only Australian Medical Research Institute (MRI) to receive a comprehensive ISO 9001 accreditation covering all operations, research and development processes. This accreditation reinforces the Bionics Institutes commitment to…
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
15 October 2019 SYDNEY, AUSTRALIA – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces mature positive efficacy data from its TACTI-mel Phase…
Tim Oldham Appointed as Chief Executive Officer of AdAlta Ltd
9.10.2019 MELBOURNE Australia: The Board of AdAlta Limited (ASX:1AD), is pleased to announce the appointment of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director. Dr Oldham has extensive skills and expertise over…
Smileyscope secures a prominent Silicon Valley investor
9 October 2019 August and September have been landmark months for Smileyscope. We welcome our largest investor to date, and are closing a funding round which will allow us to grow rapidly through the next 18 months. Our…
